<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75513">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01860144</url>
  </required_header>
  <id_info>
    <org_study_id>CGOG2001</org_study_id>
    <nct_id>NCT01860144</nct_id>
  </id_info>
  <brief_title>An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational, multicenter, prospective study will evaluate the use of bevacizumab in
      real clinical practice in chinese patients with metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the treatment response of bevacizumab in Chinese patients with mCRC in real clinical practice</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 3 months till death or lost</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>the follow-up visit of PFS will be performed every 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with bevacizumab treatment discontinuation</measure>
    <time_frame>3 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Proportion of patients with bevacizumab treatment discontinuation due to bevacizumab-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resection rate</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>resection rate of tumor after chemotherapy plus bevacizumab</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>bevacizumab</arm_group_label>
    <description>Patients with metastatic colorectal cancer who accept treatment with chemotherapy and bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>bevacizumab</arm_group_label>
    <other_name>avastin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        metastatic colorectal cancer patients accept bevacizumab
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed metastatic colorectal cancer patients Having initiated
             treatment with bevacizumab

        Exclusion Criteria:

          -  non-metastatic colorectal cancer patients not recieved bevacizumab
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hopital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Shen, M.D.</last_name>
    <phone>861088196561</phone>
    <email>lin100@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jifang Gong, M.D.</last_name>
    <phone>861088196561</phone>
    <email>gongjifang@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen, M.D.</last_name>
      <phone>861088196561</phone>
      <email>lin100@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 21, 2013</lastchanged_date>
  <firstreceived_date>May 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Director of GI oncology</investigator_title>
  </responsible_party>
  <keyword>bevacizumab</keyword>
  <keyword>overall survival</keyword>
  <keyword>adverse events</keyword>
  <keyword>tumor resection rate</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
